FDA issues warning about risks of noninvasive prenatal screening

The FDA is warning the public about the risks for false results and inappropriate interpretation of results from noninvasive prenatal screening tests, which could lead to “improper medical decisions,” according to the agency.
Noninvasive prenatal screening (NIPS) tests can provide information on the possibility that a fetus may have a genetic abnormality, but the FDA stressed that these are not diagnostic tools and additional testing is needed to confirm abnormalities. Despite this, the FDA has received reports that patients have ended pregnancies based on the results of NIPS

The FDA is warning the public about the risks for false results and inappropriate interpretation of results from noninvasive prenatal screening tests, which could lead to “improper medical decisions,” according to the agency.
Noninvasive prenatal screening (NIPS) tests can provide information on the possibility that a fetus may have a genetic abnormality, but the FDA stressed that these are not diagnostic tools and additional testing is needed to confirm abnormalities. Despite this, the FDA has received reports that patients have ended pregnancies based on the results of NIPS